



Lund November 17, 2020

Press Release

Neutraceutical Patent granted in Europe

Hamlet Pharma AB has secured patent protection in Europe for milk-based neutraceutical products that have been prepared using a mild process that generates neutraceutically beneficial complexes. This is the subject of European patent EP 3295953 B1. The patent is valid until August 8, 2033.

The patent is based on extensive academic research and discoveries made by researchers at Lund University. With this patent, Hamlet Pharma AB continues to expand its intellectual property portfolio to cover further areas where its key products show benefit.

‘Bamlet is a molecule with beneficial effects. Through a neutraceutical preparation, Bamlet will reach consumers who can benefit from these effects’ says Catharina Svanborg, CMO and chairman of the board of Hamlet Pharma Ltd.

“We are very proud that this patent has been granted in Europe” says Mats Persson, CEO of Hamlet Pharma Ltd.

For more information, please contact

Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49
catharina.svanborg@med.lu.se

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
mats.persson@hamletpharma.com

About HAMLET Pharma

HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and



Lund November 17, 2020

has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α -lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.

This information is insider information that Hamlet Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above, on November 17, 2020.